Eight patients have been enrolled to date in Rein Therapeutics’ randomized, placebo-controlled Phase 2 RENEW trial of LTI-03 for idiopathic pulmonary fibrosis, with two additional enrollments expected imminently. Enrollment began in March 2026. The study is targeting approximately 120 patients across two dose cohorts versus placebo, with change from baseline in forced vital capacity as the primary efficacy endpoint. Sites are active in the United States, Australia, and Poland, with the United Kingdom and Germany slated to open next.
The update signals an early ramp in a multi-country footprint for a mid-stage IPF program built around an inhaled peptide derived from Caveolin-1 biology. RENEW is structured to assess safety, tolerability, and efficacy for LTI-03’s proposed dual action—modulating profibrotic signaling while supporting alveolar epithelial repair—within a conventional functional endpoint framework. The geographic mix suggests Rein is balancing established IPF referral ecosystems with markets that can activate quickly and sustain steady screening pipelines.
Strategically, the move reads as enrollment insurance and regulatory optionality. IPF studies compete for a finite patient pool concentrated in specialist centers, and FVC-driven designs typically require longer on-study durations to demonstrate effect. With roughly one to two months of activity yielding eight patients, the early cadence is acceptable but not yet at a pace that would close a 120-patient trial on an aggressive timeline. Opening the U.K. and Germany should add capacity and broaden investigator familiarity, while Australia and Poland can diversify referral sources and smooth seasonal and regional variability in screening. The inhaled route adds differentiation but also operational load: device training, standardized administration, and cross-site harmonization of spirometry and PFT quality controls become gating factors as geographies multiply.
For sites, the implications are practical. Coordinating inhaled dosing procedures alongside high-fidelity spirometry requires workflow discipline, consistent technician training, and tight calibration practices—ideally with central oversight to minimize inter-site variability. If background antifibrotics are permitted, as is common in IPF, medication reconciliation and stability windows can affect screening yields and data interpretability; if they are not, recruitment friction tends to rise. CROs and vendors will need to align device logistics, supply chains, and PFT QA across regulatory environments, while building patient-support infrastructure for inhalation technique and adherence. For regulators, a clean read across multiple regions strengthens external validity but raises the bar on consistent endpoint execution; early clarity on secondary measures and exacerbation capture will matter if FVC differences are modest.
The near-term marker to watch is enrollment velocity as U.K. and German sites come online and as additional centers are activated beyond the initial three countries. Operational signals—on-time site initiations, device availability, central spirometry adoption, and early discontinuation trends—will indicate whether the program can sustain a mid- to high-single-digit monthly enrollment rate needed to finish on a reasonable clock. Methodologically, details that remain unspecified in this update will be consequential: allowance and stratification for background therapy, imaging or physiologic secondary endpoints that buttress FVC, and plans for interim safety or futility looks. Longer term, dose selection discipline and manufacturing-readiness for an inhaled peptide plus device pairing will shape any Phase 3 path. Competition for IPF patients is intensifying, and programs that can demonstrate operational reliability alongside a tolerability edge will have the advantage when they seek to convert mid-stage signals into registrational momentum.
Source link: https://www.globenewswire.com/news-release/2026/04/29/3283690/28652/en/Rein-Therapeutics-Provides-Clinical-Trial-Update-for-Phase-2-RENEW-Study-of-LTI-03-in-Idiopathic-Pulmonary-Fibrosis.html
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
